Rosustar

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rosustar

Quick Facts

Property Description
Active Ingredient Rosuvastatin calcium
Form Film-coated tablets
Pharmacological Class HMG-CoA reductase inhibitor (Statin)
General Purpose Modifying blood lipid profiles
Origin Synthetic compound

What is Rosustar? Defining the Therapeutic Entity

Rosustar is a prescription-only medicine containing the active pharmaceutical substance Rosuvastatin calcium. This drug is a synthetic compound administered in the form of a film-coated tablet intended for oral administration. The formulation is a single-ingredient product, meaning its therapeutic effect relies solely on the action of the Rosuvastatin calcium component combined with standard pharmaceutical excipients.

Pharmacological Class and General Purpose

Rosuvastatin calcium belongs to the class of HMG-CoA reductase inhibitors, which are universally known as statins or antilipemic agents. This classification identifies the medicine as one designed to specifically modulate lipid metabolism. Statins work by limiting the liver's ability to produce cholesterol. Rosuvastatin is clinically recognized for its high potency within the statin class, often employed when effective and reliable lowering of blood lipids is necessary.

The fundamental purpose of Rosustar is the systemic regulation and improvement of the body's lipid profiles, acting as a potent antilipemic agent. Its mechanism involves functioning as a selective competitive inhibitor of the rate-limiting enzyme in cholesterol biosynthesis. The resulting decrease in the liver's internal cholesterol production leads to an enhanced clearance of circulating low-density lipoprotein cholesterol (LDL-C), thereby defining its primary role in reducing the overall burden of harmful fats in the bloodstream, such as in cases where a patient needs to manage high cholesterol levels.

What side effects are possible with Rosustar?

Possible side effects and safety information

Rosustar's safety profile, defined by regulatory authorities, outlines potential adverse effects classified by frequency and affected body system. The active ingredient, Rosuvastatin, is associated with reactions categorized across several domains, primarily Musculoskeletal and Connective Tissue Disorders, Gastrointestinal Disorders, and Hepatobiliary Disorders.

Frequency-Classified Adverse Reactions

The regulatory documents classify side effects into incidence tiers. Common adverse reactions, reported in up to 1 in 10 patients, include myalgia (muscle pain), headache, constipation, nausea, dizziness, asthenia (weakness), and the potential for new-onset Diabetes Mellitus. Uncommon reactions may involve skin effects like rash, pruritus (itching), or urticaria.

Serious Adverse Reactions and Safety Constraints

The official labeling notes the possibility of rare but serious adverse reactions, which include rhabdomyolysis and myopathy, potentially impacting kidney function. Other rare severe effects are pancreatitis and hepatic failure. Post-marketing reports document cases of Interstitial Lung Disease (ILD) and Immune-Mediated Necrotizing Myopathy (IMNM).

Regulatory documents highlight specific safety constraints and population considerations. Rosustar is contraindicated in patients with pre-existing conditions such as active liver disease, unexplained persistent elevations of liver enzymes, severe renal impairment, or existing myopathy. Furthermore, specific monitoring is recommended because increased systemic exposure has been documented in individuals of Asian descent. Proteinuria is generally a transient finding that may be observed more frequently at the highest dose.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information states that no specific antidote is known for an overdose of Rosustar (rosuvastatin). Treatment is strictly limited to symptomatic and supportive measures, as described in government prescribing information.

Documented Overdose Manifestations and Risks

Domain Official Regulatory Statement
Documented Manifestations No unique symptom profile is documented; presentations are an exacerbation of known severe adverse reactions.
Serious Outcomes The primary concern is Rhabdomyolysis (severe muscle breakdown), which can lead to acute renal failure secondary to myoglobinuria. Markedly elevated Creatine Kinase and serum transaminases are expected laboratory findings.

Official Emergency Actions

If an overdose is suspected, government regulatory documents mandate that individuals seek immediate medical attention or go to the nearest hospital emergency room right away. Supportive procedures required in a hospital setting include continuous observation and monitoring of Creatine Kinase (CK) and Liver Function Tests. Due to the high plasma protein binding of rosuvastatin, hemodialysis is not expected to be of significant benefit in enhancing drug clearance. Management focuses entirely on stabilizing the patient and treating the symptomatic effects of toxicity.

Therapeutic Uses of Rosustar

Rosustar (Rosuvastatin) is a medicine commonly used in situations involving certain distressing symptoms related to high blood fat levels. It may be part of symptomatic management in clinical settings where supportive symptomatic assistance is needed for **conditions presenting with systemic or localized discomfort.

The core therapeutic domains include primary hypercholesterolemia, mixed dyslipidemia, and homozygous familial hypercholesterolemia. As an adjunct to diet and exercise, it may assist with reducing the risk of major cardiovascular events, such as stroke, myocardial infarction (heart attack), and the need for arterial revascularization procedures. This supportive role may contribute to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for symptoms that create noticeable physiological strain.

The medicine may be considered relevant when supportive symptom management is appropriate, and may help patients cope more steadily. “It is commonly used to help with conditions involving episodic or fluctuating manifestations and supports general well-being during symptomatic phases.”

Eligibility and Restrictions for Use

Absolute Contraindications

Rosustar is contraindicated and must not be used in several patient populations, according to regulatory guidelines. These absolute exclusions include individuals with a known hypersensitivity to any component of the medicine, patients with active liver disease (defined by persistent, unexplained elevations of liver enzymes), and those receiving the medication Ciclosporin. Furthermore, the medicine is contraindicated for women who are pregnant or may become pregnant, and for nursing mothers.


Restricted Use and Special Populations

Eligibility is limited or conditional for specific groups. The maximum 40 mg dose is contraindicated for patients with moderate kidney impairment (renal insufficiency), individuals of Asian ancestry, and those with pre-disposing factors for myopathy, such as uncontrolled hypothyroidism or hereditary muscle disorders. For patients with severe kidney impairment, use is restricted, often with a regulatory limit on the maximum permissible dose. The medicine is approved for adults and certain pediatric patients (typically starting at age 6 or older for specific conditions), but use is not recommended in children younger than six years of age.

What should I know about interactions with other medicines?

The Rosuvastatin interaction profile is governed by the drug’s processing via specific transport proteins, primarily OATP1B1 and BCRP. Inhibition of these transporters is the principal mechanism for an officially documented increase in the drug's systemic exposure, necessitating strict constraints or co-administration restrictions defined by regulatory agencies.

Official Regulatory Constraints

Interaction Type Interacting Substance Regulatory Constraint
Contraindicated Use Ciclosporin Co-administration is strictly prohibited due to a significant, labeled increase in Rosuvastatin plasma exposure.
Dose-Limited PK Gemfibrozil Use should generally be avoided; if necessary, the Rosuvastatin dose must not exceed 10 mg daily.
Dose-Limited PK Lopinavir/Ritonavir, Atazanavir/Ritonavir The Rosuvastatin dose must be limited to 10 mg daily due to increased systemic exposure.
Pharmacodynamic Risk Other Fibrates, Colchicine Co-administration increases the documented, additive risk of skeletal muscle effects (myopathy and rhabdomyolysis).
Coagulation Effect Coumarin Anticoagulants (e.g., Warfarin) Requires frequent monitoring of the International Normalised Ratio (INR), as Rosuvastatin may prolong this value.

An administration-timing rule is mandated for certain co-administered over-the-counter products: Rosuvastatin must be administered at least 2 hours before an Aluminum and Magnesium Hydroxide Combination Antacid to prevent reduced absorption. Population-specific cautions, such as increased systemic exposure observed in Asian patients and the heightened relevance of interactions in severe renal impairment, are officially noted in regulatory labeling.

Mechanism of Action

How Rosustar Works: Mechanism of Action

Rosustar (Rosuvastatin) operates through two primary and interconnected mechanistic domains centered in the liver, leading to physiological modification of lipid profiles and vascular function.


Targeting Cholesterol Synthesis and Hepatic Uptake

Rosuvastatin works primarily by acting as a selective competitive inhibitor of the enzyme HMG-CoA reductase, which is the rate-limiting step for cholesterol production within hepatocytes (liver cells). This initial molecular action depletes the liver's internal cholesterol supply. As a result, the hepatocyte membrane increases the number of LDL receptors on its surface to compensate, resulting in enhanced clearance of Low-Density Lipoprotein Cholesterol (LDL-C) from the bloodstream. This dual mechanism of suppressing synthesis and accelerating clearance contributes to the drug's core physiological consequence: a systemic reduction in circulating LDL-C.


️ Cholesterol-Independent Vascular Modulation

Beyond lipid reduction, Rosuvastatin engages in secondary pleiotropic effects that are independent of lipid concentration. By inhibiting the Mevalonate pathway, the drug limits the production of essential isoprenoid intermediates. This action indirectly modulates the activity of regulatory proteins (GTPases) that influence the function of blood vessel linings. This mechanistic domain contributes to improved endothelial function by increasing Nitric Oxide bioavailability, supporting the drug's overall cardiovascular physiological effect profile.

Dosage and Administration Information

How to use Rosustar: Administration Guidelines

Rosustar (rosuvastatin) is prescribed for oral administration as a film-coated tablet, designed to be taken once daily.

Dosage and Frequency

The dosage schedule defines the range of use:

Instruction Category General Adult Guideline Population-Specific Rule (Examples)
Starting Dose Typically 10 mg or 20 mg once daily. 5 mg once daily recommended for Asian patients or those with severe renal impairment.
Dose Range 5 mg to 40 mg once daily. Dose should not exceed 10 mg once daily for patients with severe renal impairment (not on hemodialysis).
Titration Interval Dose adjustments are made after a minimum of 2 to 4 weeks.
Maximum Dose 40 mg once daily, generally reserved for specific patients not adequately controlled on lower doses.

General Administration Rules

For proper use, the tablet may be taken with or without food and at any time of day, though a consistent time is advisable. The tablet must be swallowed whole and should not be crushed or chewed.

If a dose is missed, it is advised to resume with the next scheduled dose and not to take an extra dose to compensate. A procedural restriction exists for antacids: Rosustar should be administered at least two hours before any antacid containing aluminum and magnesium hydroxide to avoid potential effects on absorption.

This structured protocol defines the full scope of use.

Recent Clinical Evidence

Rosustar: Recent Clinical Evidence


Evidence for Use in Managing High Cholesterol (Dyslipidemia)

Research has primarily examined the use of this medicine in the context of lipid modification. This evidence is based on short-term, randomized controlled trials (RCTs) conducted in adult patients diagnosed with hyperlipidemia and mixed dyslipidemia. The research primarily examined changes in biomarkers such as Low-Density Lipoprotein Cholesterol (LDL-C) and High-Density Lipoprotein Cholesterol (HDL-C) over short intervals. Findings describing patterns of lower measured LDL-C and higher measured HDL-C were reported. The existing research predominantly focuses on short-term biomarker shifts rather than long-term clinical outcomes like heart events, meaning limited information for long-term outcomes is available.


Evidence for Use in Preventing Major Cardiovascular Events

Studies have explored the role of Rosustar in reducing the risk of major events, which is classified into primary prevention (without known disease) and secondary prevention (with existing disease). For primary prevention, large, placebo-controlled trials examined a composite outcome of major vascular events (MACE) in high-risk adults. Analysis reported measurements of fewer composite vascular events in the Rosustar group compared to the placebo group. For secondary prevention (patients with established heart disease), trials evaluated Rosustar against other existing treatments in the same pharmacological class. Pooled data show patterns related to a comparable number of major cardiovascular events in these trials.


Evidence in Special Populations: Pediatric and Genetic Forms

Research was studied for children and adolescents (typically ages 10 to 17) with Familial Hypercholesterolemia (HeFH) using small, short-term randomized trials followed by extended observation. These studies examined changes in LDL-C and monitored physical development. Controlled periods reported measurements describing lower measured LDL-C levels compared to placebo. Sample sizes were modest, and there is limited information for long-term outcomes regarding the ultimate prevention of heart events decades later in this specific group.


What is Still Uncertain About Rosustar: Evidence Gaps

Understanding the research structure requires acknowledging limitations. Follow-up durations were limited in many primary efficacy studies. Comparative evidence is lacking for a distinct advantage over other treatments in the same pharmacological class in every high-risk subgroup. Data for certain groups remain insufficient, such as patients with multiple complex, long-term conditions. Research provides context on group patterns, not individual predictions for these long-term outcomes.

Key Studies & References

  1. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein (JUPITER Trial)

Frequently Asked Questions (FAQ)

Common questions about Rosustar (FAQ)

Q: How quickly can I expect Rosustar to lower my cholesterol?

A: Studies indicate that the cholesterol-lowering effects of Rosustar begin relatively quickly. The time frame for assessing the drug's effectiveness, such as changes in LDL-C (low-density lipoprotein cholesterol) levels, is often considered appropriate after approximately 4 weeks of treatment or dose adjustment.

Q: Can I drink alcohol while I am on Rosustar?

A: Official information advises patients to be cautious about alcohol consumption while taking this medicine. Consuming alcohol may increase the risk of liver-related problems associated with Rosustar. The regulatory guidance advises individuals to consult with a healthcare professional regarding their alcohol intake while using this medicine.

Q: What foods or supplements should I avoid when taking Rosustar?

A: The official product information specifically requires that Rosustar be taken at least 2 hours before antacids that contain aluminum and magnesium. Taking other cholesterol-lowering medicines, such as fibrates (like gemfibrozil), may also increase the risk of muscle problems. For personalized guidance, any changes to diet or the addition of new supplements should be reviewed with a healthcare professional.

Q: Is it safe to take Rosustar with blood pressure medication?

A: Regulatory information indicates that Rosustar is not broadly contraindicated (absolutely forbidden) with all blood pressure medications. However, co-administration with any drug may require dose adjustments to avoid increased systemic exposure and potential side effects. It is important that a healthcare professional is informed about all co-administered medicines, including those for high blood pressure.

Q: What are the general rules for stopping Rosustar?

A: Official guidance indicates that Rosustar therapy should be continued unless a healthcare professional advises otherwise. If severe muscle symptoms occur and muscle damage (myopathy) is diagnosed, the medicine is typically discontinued. In some cases, if symptoms resolve, a healthcare professional may decide to restart the drug at a lower dose under supervision.

Q: Will Rosustar help prevent a heart attack?

A: The medicine is indicated to reduce the risk of major adverse cardiovascular events in certain high-risk adult patients. This includes reducing the risk of a myocardial infarction (commonly known as a heart attack) and stroke.

Q: What research supports the use of Rosustar for heart disease prevention?

A: Clinical studies have been conducted to evaluate the drug's role in prevention. Studies such as the JUPITER trial examined patterns of a reduction in the risk of major cardiovascular events in high-risk patients compared to a placebo. This research provided the basis for its indication in high-risk populations.

Q: Does Rosustar interact with grapefruit juice?

A: The official regulatory label for Rosustar does not specifically mention an interaction with grapefruit juice. However, because food and drink interactions can vary among statin medicines, you should raise any specific concerns with your prescribing professional.

Q: Is Rosustar prescribed for women differently than for men?

A: Specific warnings exist for women of childbearing age. The drug is not recommended for women who are pregnant or nursing due to potential risk to the fetus or infant. For personalized guidance regarding use in high-risk women of childbearing potential, consultation with a healthcare professional is necessary.

Q: What does Rosustar do to HDL (good) cholesterol?

A: In addition to lowering 'bad' cholesterol (LDL-C), official indications state that the drug is also used as an adjunct to diet to increase levels of High-Density Lipoprotein Cholesterol (HDL-C), which is commonly referred to as 'good' cholesterol.

Q: Is Rosustar the same as Crestor?

A: Crestor is one of the brand names used to market a product that contains the same active ingredient as Rosustar, which is rosuvastatin calcium. Therefore, the core medication component and its primary action are the same.

Q: Can Rosustar cause memory problems or confusion?

A: Official postmarketing reports have included instances of memory loss and confusion in patients taking statins. These effects are generally not considered serious and are typically reversible after the statin is stopped.

Q: Are there any long-term effects of taking Rosustar?

A: While the drug is intended for long-term use, the longest clinical studies used for major indications had a limited median follow-up duration (e.g., about two years). Long-term effects and risks beyond the duration of these controlled studies are continually monitored and assessed by regulatory agencies.

Q: Is Rosustar safe for people with diabetes?

A: Official information notes that Rosustar has been associated with increases in HbA1c (a measure of long-term blood sugar) and Fasting Serum Glucose levels. Official information suggests that patients with diabetes may require close monitoring of their blood sugar levels by a healthcare professional while using this drug.

Q: Will my cholesterol levels go back up if I stop taking Rosustar?

A: The cholesterol-lowering effect is generally dependent on continuous use of the drug. Since high cholesterol is typically a chronic condition, stopping the medicine will likely result in your cholesterol levels returning to the pre-treatment levels over time.

Q: Can Rosustar make me feel tired or weak?

A: Yes, asthenia (a term for general weakness or lack of energy) is listed in official documents as a common adverse reaction reported in clinical trials.

Q: What is the typical age range for people taking Rosustar?

A: Rosustar is approved for use in adults and for specific inherited high cholesterol conditions in pediatric patients starting as young as 7 or 8 years old. Its use in primary prevention is often studied in high-risk adults, such as men 50 years and older and women 60 years and older.

Q: Are there any special considerations for older adults taking Rosustar?

A: Yes, official guidelines note that the risk of muscle-related side effects, such as myopathy and rhabdomyolysis, is considered a risk factor in patients 65 years or older. This risk factor should be monitored and managed carefully by a healthcare professional.

Q: Does Rosustar affect kidney function?

A: The drug is associated with potential kidney risk if a severe muscle breakdown condition (rhabdomyolysis) occurs. Additionally, proteinuria (protein in the urine), which is generally a transient finding, has been observed in some patients, especially at the highest dose.

Q: Are there common signs that Rosustar is starting to work?

A: There are typically no noticeable physical signs a patient would feel when the drug is starting to work. The drug’s effects are confirmed by measuring changes in blood lipid levels, which is generally done via blood tests after approximately four weeks of use.

Q: Can I take pain relievers like Tylenol or Advil with Rosustar?

A: The regulatory label does not specifically mention interactions with common over-the-counter pain relievers like acetaminophen (Tylenol) or ibuprofen (Advil). However, caution is generally advised for any medicine that affects the liver, and it is important that a healthcare professional is informed about all pain relievers being used.

Q: Is it normal to have mild nausea when starting Rosustar?

A: Yes, nausea is listed in official product information as a common adverse reaction reported in clinical trials. This means it is a known effect that may occur when initiating therapy with the drug.

Q: How long does Rosustar stay in your system?

A: Regulatory information on the drug’s processing in the body indicates it has a relatively long elimination half-life of approximately 19 hours. This is the time it takes for half of the drug to be eliminated from your system.

Q: Does taking Rosustar affect my body weight?

A: Changes in body weight are not listed as a common or serious adverse reaction in the official regulatory documentation from clinical trials.

Q: Is Rosustar used to treat high triglycerides as well as high LDL?

A: Yes, the drug is officially indicated as an adjunct to diet. Its indicated uses include reducing elevated levels of both triglycerides and LDL-C ('bad' cholesterol).

Q: Is Rosustar safe for people who have had a stroke?

A: The drug is indicated to reduce the risk of a stroke in certain high-risk adult patients, reflecting its use in cardiovascular risk management. This means it has a role in managing risk factors for relevant populations.

Q: What is the connection between Rosustar and muscle breakdown (rhabdomyolysis)?

A: Rosustar belongs to the statin class, which works by inhibiting an enzyme in the body. Muscle toxicity, ranging from simple pain to severe breakdown (rhabdomyolysis), is a known but rare complication that can occur due to the drug's core mechanism of action.

Q: How does Rosustar compare to lifestyle changes alone?

A: The drug is officially indicated as an adjunct to diet and exercise. This means it is intended to work in combination with, and not as a replacement for, appropriate lifestyle changes.

Q: Are there specific symptoms that mean I should call a doctor while on Rosustar?

A: Symptoms such as unexplained muscle pain, tenderness, or weakness, especially if accompanied by fever or unusual tiredness, are recognized signs that warrant immediate contact with a healthcare professional, as they can indicate a rare but serious muscle condition.

Q: What percentage of people experience side effects from Rosustar?

A: Official regulatory documents list side effects by frequency tiers (e.g., Common: affects up to 1 in 10 patients) but do not provide a single, overall percentage of people who experience any side effect.

Q: Can Rosustar interact with contraceptive pills?

A: Regulatory documents provide specific guidance for certain types of oral contraceptives. The medicine may increase the blood levels of these contraceptives. The specific combination of these medicines should be reviewed by a healthcare professional to determine if monitoring is needed.

Q: Can taking Rosustar affect my sleep?

A: Postmarketing reports have noted some potential for sleep abnormalities, which include instances of both insomnia and nightmares. However, these are not listed as common side effects of the drug.

Q: Is Rosustar effective for people who already eat a healthy diet?

A: Yes, the drug is officially indicated as an adjunct to diet. This means that Rosustar is intended to work in combination with, not in place of, appropriate dietary guidelines for managing cholesterol.

Q: Why do doctors check my blood work when I start Rosustar?

A: Blood tests are typically conducted before and during treatment to monitor the proper functioning of the liver and muscles and to measure the drug's effectiveness on cholesterol levels. This is a standard safety and monitoring procedure.

Q: Can I take other cholesterol-lowering supplements with Rosustar?

A: Combining this drug with other agents used to lower cholesterol, such as certain supplements or drugs like fibrates and high-dose niacin, may increase the risk of muscle-related side effects. For personalized guidance on combining these agents, consultation with a healthcare professional is necessary.

Q: Is Rosustar considered a standard treatment for high cholesterol?

A: The drug belongs to the statin class of medicines, which are widely accepted and routinely used as a first-line therapy (or primary treatment) to lower LDL-C in eligible patients when lifestyle changes alone are insufficient.

Q: Why is it important to keep taking Rosustar even if I feel fine?

A: The conditions treated, such as high cholesterol, are generally chronic and often have no noticeable symptoms. Continuous use is typically required to maintain the lowering of cholesterol and the resulting long-term reduction in the risk of heart attack or stroke.

Q: Can children or teenagers ever take Rosustar?

A: Yes, the drug is approved for use in certain pediatric patients, typically those aged 7 years and older. This use is specifically for children diagnosed with certain forms of inherited high cholesterol (familial hypercholesterolemia).

How should Rosustar be stored and disposed of?

How to Store and Dispose of Rosustar?

Rosuvastatin tablets must be stored according to specific environmental and container requirements to maintain their stability, as defined in regulatory labeling.

Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep the medicine in its original container, tightly closed, and protect it from moisture, direct heat, and light.
Child Safety Store the medicine out of the sight and reach of children and pets.

Disposal Instructions

Unused or expired Rosuvastatin must be disposed of properly to protect the environment. The medicine must not be flushed down a toilet or poured down a drain unless specifically instructed by an authorized program. Disposal should adhere to local regulations and guidelines for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rosustar found in:

A-Z Index: